OTLK Outlook Therapeutics Inc.

0.76
+0.01  (+1%)
Previous Close 0.75
Open 0.77
Price To Book -1.06
Market Cap 40,392,352
Shares 53,147,832
Volume 502,318
Short Ratio
Av. Daily Volume 1,051,137
Stock charts supplied by TradingView

NewsSee all news

  1. Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market

    CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  2. Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market

    CRANBURY, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  3. Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020

    CRANBURY, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  4. Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference

    CRANBURY, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"),  a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  5. Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010

    CRANBURY, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due August 2020.
NORSE 1 (ONS-5010-001)
Wet age-related macular degeneration (wet AMD)
Phase 3 data due 1H 2021.
NORSE 2 (ONS-5010-002)
Wet age-related macular degeneration (wet AMD)
Phase 3 trial to be initiated in 2020.
NORSE 4 (ONS-5010)
Branch retinal vein occlusion (BRVO)
Phase 3 trials to be initiated in 2020.
NORSE 5 and 6 (ONS-5010)
Diabetic macular edema (DME)

Latest News

  1. Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market

    CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  2. Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market

    CRANBURY, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  3. Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020

    CRANBURY, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  4. Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference

    CRANBURY, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"),  a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  5. Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010

    CRANBURY, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  6. Outlook Therapeutics Announces Completion of Warrant Restructuring

    CRANBURY, N.J., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  7. Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions

    CRANBURY, N.J., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic

  8. Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019

    Topline results from the NORSE 1 study of ONS-5010 expected to be announced in the third quarter of calendar 2020Enrollment in the NORSE 2 study underwaySPA agreement reached with FDA for NORSE 4, 5 and 6 studies

  9. Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010

    ONS-5010, an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two clinical trials to treat wet age-related macular degeneration (wet AMD – NORSE 1 and 2). SPAs for clinical

  10. Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference

    CRANBURY, N.J., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company") today announced that it is scheduled to participate in the Ladenburg Thalmann 2019 Healthcare Conference being

  11. Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference

    CRANBURY, N.J., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company") today announced that it is scheduled to participate in the H.C. Wainwright 21st Annual Healthcare Conference